

Table 1. Publications of trial and registry data included in HoLISTIC Consortium

	Years accrual ^a	Author, Year published
Early Stage Trial		
EORTC H9U	1998 – 2002	Ferme et al 2017 ¹
EORTC H10	2006 – 2011	Raemaekers et al 2014, ² Andre et al 2017 ³ and Federico et al 2024 ⁴
NCIC-ECOG	1994 – 2002	Meyer et al 2005 ⁵ and Meyer et al 2012 ⁶
RAPID	2003 – 2010	Radford et al 2015 ⁷ and Radford et al 2024 ⁸ (Illidge et al 2020 ⁹ ; Phillips et al 2025 ¹⁰ - <i>RAPID cohort validated in H10 trial</i>)
Advanced Stage Trial		
ECOG2496	1999 – 2006	Gordon et al 2013, ¹¹ Evens et al 2013 ¹² and Advani et al 2015 ¹³
Italian HD0607	2008 – 2014	Gallamini et al 2018 ¹⁴ and Gallamini et al 2020 ¹⁵
Italian IIL HD0801	2008 – 2013	Zinzani et al 2016 ¹⁶
Italian HD2000	2000 – 2007	Federico et al 2009 ¹⁷ and Merli et al 2016 ¹⁸
Italian IIL HD9601	1996 – 2000	Gobbi et al 2005 ¹⁹ and Chisesi et al 2011 ²⁰
LYSA AHL2011	2011 - 2014	Casasnovas et al 2019 ²¹
RATHL	2008 – 2012	Johnson et al 2016 ²² and Luminari et al 2024 ²³
Stanford V-UK ISRCTN	1998 - 2006	Hoskin et al 2009 ²⁴
SWOG 0816	2009 – 2012	Press 2016 et al ²⁵ and Stephens et al 2019 ²⁶
Relapse		
LYSA PVAB	2015-2018	Ghesquieres et al 2024 ²⁷
REGISTRY		
Australia	2016-2022	Jalali et al 2016 ²⁸ and Lymphoma, Related Diseases Registry Investigators 2022 ²⁹
BC Cancer	2000-2015	Hapgood et al 2016 ³⁰
Iowa/Mayo SPORE	2002-2015	Cerhan et al 2017 ³¹
Princess Margaret Hospital	1990-2018	Hahn et al 2017 ³²
Stanford Registry	1995-2019	Weil et al 2020 ³³
The Capital Region of Denmark/ Rigshospitalet (Nordic/Danish/LYFO)	2000-2018	Arboe et al 2016 ³⁴ and Rossetti et al 2024 ³⁵

^a Trial years per publication; Registry years per harmonized data in HoLISTIC Consortium dataset

References

1. Ferme C, Thomas J, Brice P, et al. ABVD or BEACOPP(baseline) along with involved-field radiotherapy in early-stage Hodgkin Lymphoma with risk factors: Results of the European Organisation for Research and Treatment of Cancer (EORTC)-Groupe d'Etude des Lymphomes de l'Adulte (GELA) H9-U intergroup randomised trial. *Eur J Cancer* 2017;81:45-55. DOI: 10.1016/j.ejca.2017.05.005.
2. Raemaekers JM, Andre MP, Federico M, et al. Omitting radiotherapy in early positron emission tomography-negative stage I/II Hodgkin lymphoma is associated with an increased risk of early relapse: Clinical results of the preplanned interim analysis of the randomized EORTC/LYSA/FIL H10 trial. *J Clin Oncol* 2014;32(12):1188-1194. DOI: JCO.2013.51.9298.
3. Andre MPE, Girinsky T, Federico M, et al. Early Positron Emission Tomography Response-Adapted Treatment in Stage I and II Hodgkin Lymphoma: Final Results of the Randomized EORTC/LYSA/FIL H10 Trial. *J Clin Oncol* 2017;35(16):1786-1794. DOI: 10.1200/JCO.2016.68.6394.
4. Federico M, Fortpied C, Stepanishyna Y, et al. Long-Term Follow-Up of the Response-Adapted Intergroup EORTC/LYSA/FIL H10 Trial for Localized Hodgkin Lymphoma. *J Clin Oncol* 2024;42(1):19-25. DOI: 10.1200/JCO.23.01745.
5. Meyer RM, Gospodarowicz MK, Connors JM, et al. Randomized comparison of ABVD chemotherapy with a strategy that includes radiation therapy in patients with limited-stage Hodgkin's lymphoma: National Cancer Institute of Canada Clinical Trials Group and the Eastern Cooperative Oncology Group. *J Clin Oncol* 2005;23(21):4634-42. DOI: 10.1200/JCO.2005.09.085.
6. Meyer RM, Gospodarowicz MK, Connors JM, et al. ABVD alone versus radiation-based therapy in limited-stage Hodgkin's lymphoma. *N Engl J Med* 2012;366(5):399-408. DOI: 10.1056/NEJMoa1111961.
7. Radford J, Illidge T, Counsell N, et al. Results of a trial of PET-directed therapy for early-stage Hodgkin's lymphoma. *N Engl J Med* 2015;372(17):1598-1607. DOI: 10.1056/NEJMoa1408648.
8. Radford J WJ, Edwards D, Pettengell R, Johnson P, Hoskin P, Illidge T, Counsell N. Involved field radiotherapy versus no further treatment in patients with newly diagnosed stage 1A or 2A Hodgkin lymphoma and a 'negative' PET scan after 3 cycles ABVD. Survival and cause of death after a median of 16 years follow-up in the UK RAPID trial. *American Society of Hematology. San Diego, CA: Blood*; 2024:457.
9. Illidge TM, Phillips EH, Counsell N, et al. Maximum tumor diameter is associated with event-free survival in PET-negative patients with stage I/IIA Hodgkin lymphoma. *Blood Adv* 2020;4(1):203-206. DOI: 10.1182/bloodadvances.2019001023.
10. Phillips E, Counsell N, Illidge TM, Andre M, Aurer I, Fiaccadori V, Fortpied C, Neven A, Federico M, Barrington SF, Raemaekers JM, Radford J. Maximum Tumor Diameter is Associated with Relapse Risk in Limited-Stage Hodgkin Lymphoma: An International Study. *Blood Adv* 2025. DOI: <https://doi.org/10.1182/bloodadvances.2024015140>.
11. Gordon LI, Hong F, Fisher RI, et al. Randomized phase III trial of ABVD versus Stanford V with or without radiation therapy in locally extensive and advanced-stage Hodgkin lymphoma: an intergroup study coordinated by the Eastern Cooperative Oncology Group (E2496). *J Clin Oncol* 2013;31(6):684-691.
12. Evens AM, Hong F, Gordon LI, et al. The efficacy and tolerability of adriamycin, bleomycin, vinblastine, dacarbazine and Stanford V in older Hodgkin lymphoma patients: a comprehensive analysis from the North American intergroup trial E2496. *Br J Haematol* 2013;161(1):76-86. DOI: 10.1111/bjh.12222.
13. Advani RH, Hong F, Fisher RI, et al. Randomized Phase III Trial Comparing ABVD Plus Radiotherapy With the Stanford V Regimen in Patients With Stages I or II Locally Extensive, Bulky

- Mediastinal Hodgkin Lymphoma: A Subset Analysis of the North American Intergroup E2496 Trial. *J Clin Oncol* 2015;33(17):1936-42. DOI: 10.1200/JCO.2014.57.8138.
14. Gallamini A, Tarella C, Viviani S, et al. Early Chemotherapy Intensification With Escalated BEACOPP in Patients With Advanced-Stage Hodgkin Lymphoma With a Positive Interim Positron Emission Tomography/Computed Tomography Scan After Two ABVD Cycles: Long-Term Results of the GITIL/FIL HD 0607 Trial. *J Clin Oncol* 2018;36(5):454-462. DOI: 10.1200/JCO.2017.75.2543.
 15. Gallamini A, Rossi A, Patti C, et al. Consolidation Radiotherapy Could Be Safely Omitted in Advanced Hodgkin Lymphoma With Large Nodal Mass in Complete Metabolic Response After ABVD: Final Analysis of the Randomized GITIL/FIL HD0607 Trial. *J Clin Oncol* 2020;38(33):3905-3913. DOI: 10.1200/JCO.20.00935.
 16. Zinzani PL, Broccoli A, Gioia DM, et al. Interim Positron Emission Tomography Response-Adapted Therapy in Advanced-Stage Hodgkin Lymphoma: Final Results of the Phase II Part of the HD0801 Study. *J Clin Oncol* 2016;34(12):1376-85. DOI: 10.1200/JCO.2015.63.0699.
 17. Federico M, Luminari S, Iannitto E, et al. ABVD compared with BEACOPP compared with CEC for the initial treatment of patients with advanced Hodgkin's lymphoma: results from the HD2000 Gruppo Italiano per lo Studio dei Linfomi Trial. *J Clin Oncol* 2009;27(5):805-11. DOI: 10.1200/JCO.2008.17.0910.
 18. Merli F, Luminari S, Gobbi PG, et al. Long-Term Results of the HD2000 Trial Comparing ABVD Versus BEACOPP Versus COPP-EBV-CAD in Untreated Patients With Advanced Hodgkin Lymphoma: A Study by Fondazione Italiana Linfomi. *J Clin Oncol* 2016;34(11):1175-81. DOI: 10.1200/JCO.2015.62.4817.
 19. Gobbi PG, Levis A, Chisesi T, et al. ABVD versus modified stanford V versus MOPPEBVCAD with optional and limited radiotherapy in intermediate- and advanced-stage Hodgkin's lymphoma: final results of a multicenter randomized trial by the Intergruppo Italiano Linfomi. *J Clin Oncol* 2005;23(36):9198-207. DOI: 10.1200/JCO.2005.02.907.
 20. Chisesi T, Bellei M, Luminari S, et al. Long-term follow-up analysis of HD9601 trial comparing ABVD versus Stanford V versus MOPP/EBV/CAD in patients with newly diagnosed advanced-stage Hodgkin's lymphoma: a study from the Intergruppo Italiano Linfomi. *J Clin Oncol* 2011;29(32):4227-33. DOI: 10.1200/JCO.2010.30.9799.
 21. Casasnovas RO, Bouabdallah R, Brice P, et al. PET-adapted treatment for newly diagnosed advanced Hodgkin lymphoma (AHL2011): a randomised, multicentre, non-inferiority, phase 3 study. *Lancet Oncol* 2019;20(2):202-215. DOI: 10.1016/S1470-2045(18)30784-8.
 22. Johnson P, Federico M, Kirkwood A, et al. Adapted Treatment Guided by Interim PET-CT Scan in Advanced Hodgkin's Lymphoma. *N Engl J Med* 2016;374(25):2419-29. DOI: 10.1056/NEJMoa1510093.
 23. Luminari S, Fossa A, Trotman J, et al. Long-Term Follow-Up of the Response-Adjusted Therapy for Advanced Hodgkin Lymphoma Trial. *J Clin Oncol* 2024;42(1):13-18. DOI: 10.1200/JCO.23.01177.
 24. Hoskin PJ, Lowry L, Horwich A, et al. Randomized comparison of the stanford V regimen and ABVD in the treatment of advanced Hodgkin's Lymphoma: United Kingdom National Cancer Research Institute Lymphoma Group Study ISRCTN 64141244. *J Clin Oncol* 2009;27(32):5390-6. DOI: 10.1200/JCO.2009.23.3239.
 25. Press OW, Li H, Schoder H, et al. US Intergroup Trial of Response-Adapted Therapy for Stage III to IV Hodgkin Lymphoma Using Early Interim Fluorodeoxyglucose-Positron Emission Tomography Imaging: Southwest Oncology Group S0816. *J Clin Oncol* 2016;34(17):2020-7. DOI: 10.1200/JCO.2015.63.1119.

26. Stephens DM, Li H, Schoder H, et al. Five-year follow-up of SWOG S0816: limitations and values of a PET-adapted approach with stage III/IV Hodgkin lymphoma. *Blood* 2019;134(15):1238-1246. DOI: 10.1182/blood.2019000719.
27. Ghesquieres H, Krzisch D, Nicolas-Virelizier E, et al. The phase 2 LYSA study of prednisone, vinblastine, doxorubicin, and bendamustine for untreated Hodgkin lymphoma in older patients. *Blood* 2024;143(11):983-995. DOI: 10.1182/blood.2023021564.
28. Jalali A, Ha FJ, Chong G, et al. Hodgkin lymphoma: an Australian experience of ABVD chemotherapy in the modern era. *Ann Hematol* 2016;95(5):809-16. DOI: 10.1007/s00277-016-2611-4.
29. Lymphoma, Related Diseases Registry I. Improving outcomes for patients with lymphoma: design and development of the Australian and New Zealand Lymphoma and Related Diseases Registry. *BMC Med Res Methodol* 2022;22(1):266. DOI: 10.1186/s12874-022-01728-0.
30. Haggood G, Zheng Y, Sehn LH, et al. Evaluation of the Risk of Relapse in Classical Hodgkin Lymphoma at Event-Free Survival Time Points and Survival Comparison With the General Population in British Columbia. *J Clin Oncol* 2016;34(21):2493-500. DOI: 10.1200/JCO.2015.65.4194.
31. Cerhan JR, Link BK, Habermann TM, et al. Cohort Profile: The Lymphoma Specialized Program of Research Excellence (SPORE) Molecular Epidemiology Resource (MER) Cohort Study. *Int J Epidemiol* 2017;46(6):1753-1754i. DOI: 10.1093/ije/dyx119.
32. Hahn E, Jiang H, Ng A, et al. Late Cardiac Toxicity After Mediastinal Radiation Therapy for Hodgkin Lymphoma: Contributions of Coronary Artery and Whole Heart Dose-Volume Variables to Risk Prediction. *Int J Radiat Oncol Biol Phys* 2017;98(5):1116-1123. DOI: 10.1016/j.ijrobp.2017.03.026.
33. Weil CR, Qian Y, Von Eyben R, et al. Long-term outcomes of patients with unfavorable stage I-II classic Hodgkin lymphoma treated with Stanford V chemotherapy and limited field irradiation. *Leuk Lymphoma* 2020;61(10):2428-2434. DOI: 10.1080/10428194.2020.1768385.
34. Arboe B, Josefsson P, Jorgensen J, et al. Danish National Lymphoma Registry. *Clin Epidemiol* 2016;8:577-581. DOI: 10.2147/CLEP.S99470.
35. Rossetti S, Juul SJ, Eriksson F, et al. Long-term cause-specific mortality in adolescent and young adult Hodgkin lymphoma patients treated with contemporary regimens-A nationwide Danish cohort study. *Br J Haematol* 2024;205(4):1374-1382. DOI: 10.1111/bjh.19586.